Universal CAR-T Cells Targeting AML

Sponsor
Shenzhen Geno-Immune Medical Institute
Study ID
NCT05995041
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
6 Months - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells — BIOLOGICAL
    Infusion of CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells

Study Details

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of universal CAR T-cell products targeting CLL-1, CD33, CD38 and CD123 in patients with relapsed and refractory AML. The study also aims to learn more about the function of the universal CAR T cells and their persistency in AML patients.

Key Dates

First listed
Aug 16, 2023
Start date
Jun 1, 2026
Status verified
May 2026
Primary completion
Dec 31, 2029
Completion
Dec 31, 2030

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Multiple universal CAR T cells to treat AML

Primary Outcome Measure

Safety of infusion [ Time Frame: 6 months ]

Central Contacts

Find similar trials

Nationwide
Leukemia (other) trialsOncology trialsBlood cancer trials

Related Studies